ProCE Banner Activity

monarchE: Subgroup Analysis of Abemaciclib + Adjuvant ET vs ET Alone in Patients With High-Risk HR+/HER2- Early Breast Cancer Who Received Prior Neoadjuvant Chemotherapy

Slideset Download
Conference Coverage
In this prespecified subgroup analysis of patients with HR+/HER2- early breast cancer who received prior neoadjuvant chemotherapy, the subgroup showed a higher risk of recurrence vs the ITT population and had a numerically greater benefit for both invasive DFS and distant RFS with abemaciclib + adjuvant ET.

Released: June 07, 2021

Expiration: June 06, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis

Gilead Sciences, Inc.

GlaxoSmithKline

Ipsen Biopharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Pfizer, Inc.

Pharmacyclics LLC an AbbVie Company and Janssen Biotech Inc

Sanofi Genzyme